C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection.
Mononuclear phagocytes, which include circulating blood monocytes and differentiated tissue macrophages, are believed to play a central role in the sexual transmission of HIV infection. The ability of HIV to productively infect these cells may be influenced by action of exogenous or host-derived substances at the site of viral entry. Given the potent capacities of inflammatory mediators to stimulate anaphylatoxic and immunomodulatory functions in mucosa, the effects of complement-derived anaphylatoxins on the susceptibility of monocytes and monocyte-derived macrophages (MDM) to HIV-1 infection were examined. In our in vitro system, the susceptibility to infection was up to 40 times increased in MDM that had been exposed to C5a or C5a(desArg), but not to C3a or C3a(desArg), for 2 days before adding of virus. By contrast, the treatment with complement anaphylatoxins did not affect HIV replication in fresh monocytes. Stimulatory effect of C5a and its desArg derivative on HIV infection correlated with the increase of TNF-alpha and IL-6 secretion from MDM. All these functional effects of C5a and C5a(desArg) were reversible by treatment of cells with the mAb that functionally blocks C5aR. Taken together, these results indicate that C5a and C5a(desArg) may increase the susceptibility of MDM to HIV infection through stimulation of TNF-alpha and IL-6 secretion from these cells.
Kacani
L
L
Institut für Hygiene und Sozialmedizin, Leopold-Franzens-Universität, Ludwig-Boltzmann-Institut für AIDS-Forschung, Innsbruck, Austria. Laco.Kacani@uibk.ac.at
Bánki
Z
Z
Zwirner
J
J
Schennach
H
H
Bajtay
Z
Z
Erdei
A
A
Stoiber
H
H
Dierich
M P
MP
D000276:Adjuvants, Immunologic / Q000502:physiology*; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000096:biosynthesis / Q000276:immunology; D002478:Cells, Cultured; D015926:Complement C3a / Q000378:metabolism; D015936:Complement C5a / Q000378:metabolism / Q000502:physiology*; D015937:Complement C5a, des-Arginine / Q000502:physiology*; D016207:Cytokines / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007113:Immunity, Innate; D015850:Interleukin-6 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000821:virology; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D008565:Membrane Proteins; D009000:Monocytes / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014779:Virus Replication / Q000276:immunology
D000276:Adjuvants, Immunologic; D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015937:Complement C5a, des-Arginine; D016207:Cytokines; D015850:Interleukin-6; D008565:Membrane Proteins; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement; D014409:Tumor Necrosis Factor-alpha; C085567:complement C3a receptor; D015926:Complement C3a; D015936:Complement C5a